Polen Thomas E Jr sold 2,993 shares of BECTON DICKINSON CO at $210.00 for −$629k on Nov 5, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chairman, CEO and President
Chairman, CEO and President
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$628,530Shares × reported price
Shares traded
2,993Common Stock
Price per share
$210.00Reported price. Read footnotes for ranges.
% of reported position traded
2.65%This security and ownership context
Holdings after
110,163Direct
Trade date
Nov 5, 2026Sell
Filed
Nov 9, 2026, 5:44 PM ET4-day reporting delay
Accession
0001628280-26-072360Code S · Transaction 396352
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 113,156 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Option exercise20,239$0.00$0Trade 396353
Nov 5, 2026Option exercise20,239$178.94$3,621,566.66Trade 396350
Nov 5, 2026Disposition to issuer17,246$210.00−$3,621,660Trade 396351
4 transaction rows in this filing. Joint filers share the same rows.

BDX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BDX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −16%1w ago −7.9%1d ago −2.8%
Returns since7d30d90d180d1y

Footnotes in full

F1: Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2: The stock appreciation rights vest in four annual installments beginning November 26, 2019.